MicroRNA-940 as a Potential Serum Biomarker for Prostate Cancer

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Prostate cancer remains a significant cause of mortality despite high survival rates for localized disease.
• Current diagnostic methods like prostate-specific antigen (PSA) testing have limitations requiring careful risk-benefit assessment.
• MicroRNAs (miRNAs) are emerging as stable, non-invasive biomarkers for cancer prognosis and diagnosis.

Purpose of the Study:

• To investigate the diagnostic utility of circulating miR-940 as a novel molecular marker for prostate cancer.
• To assess miR-940 levels in cell culture supernatants, patient serum, and urine samples.
• To evaluate the combined diagnostic performance of miR-940 and PSA for prostate cancer detection.

Main Methods:

• Quantification of circulating miR-940 in serum and urine samples from prostate cancer patients and controls.
• Analysis of miR-940 expression in cell culture supernatants.
• Receiver operating characteristic (ROC) curve analysis to determine the diagnostic accuracy of miR-940 alone and in combination with PSA.

Main Results:

• Circulating miR-940 levels were significantly elevated in the serum of prostate cancer patients, particularly those with clinically significant tumors (Gleason score ≥ 7).
• The combination of miR-940 and PSA demonstrated a higher area under the curve (AUC: 0.818) compared to miR-940 alone (AUC: 0.75) in diagnosing prostate cancer.
• miR-940 showed potential as a biomarker in both serum and urine samples.

Conclusions:

• Circulating miR-940 is a promising biomarker for the non-invasive diagnosis of prostate cancer.
• Combining miR-940 with PSA can enhance diagnostic accuracy, offering a potential improvement over current methods.
• Further validation is warranted to establish miR-940 as a routine diagnostic tool for prostate cancer.